Xanamem depression trial published in British J Psychiatry
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced the publication of results from its phase two depression trial of Xanamem in the British Journal of Psychiatry, highlighting its potential as a novel antidepressant in difficult-to-treat patients. The trial demonstrated meaningful antidepressant activity, although improvements in cognition did not correlate with improvements in depression symptoms.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW third positive XanaMIA trial data committee review
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- Actinogen receives positive scientific advice from EMA
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
Later from Actinogen Medical
- Application for quotation of securities - ACW
- June 2026 Quarterly activity report & Appendix 4C
- ACW webinar on the future of Alzheimers treatment
- ACW Bioshares presentation, strong cortisol rationale
- Notification of cessation of securities - ACW
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical